45 related articles for article (PubMed ID: 25433245)
21. Potential Use of Biological Proteins for Liver Failure Therapy.
Taguchi K; Yamasaki K; Seo H; Otagiri M
Pharmaceutics; 2015 Aug; 7(3):255-74. PubMed ID: 26404356
[TBL] [Abstract][Full Text] [Related]
22. Hinge-Deficient IgG1 Fc Fusion: Application to Human Lactoferrin.
Shiga Y; Murata D; Sugimoto A; Oshima Y; Tada M; Ishii-Watabe A; Imai K; Tomii K; Takeuchi T; Kagaya S; Sato A
Mol Pharm; 2017 Sep; 14(9):3025-3035. PubMed ID: 28763236
[TBL] [Abstract][Full Text] [Related]
23. Albumin fusion at the N-terminus or C-terminus of human lactoferrin leads to improved pharmacokinetics and anti-proliferative effects on cancer cell lines.
Ueda K; Shimizu M; Ohashi A; Murata D; Suzuki T; Kobayashi N; Baba J; Takeuchi T; Shiga Y; Nakamura M; Kagaya S; Sato A
Eur J Pharm Sci; 2020 Dec; 155():105551. PubMed ID: 32946958
[TBL] [Abstract][Full Text] [Related]
24. Novel recombinant human lactoferrin: differential activation of oxidative stress related gene expression.
Kruzel ML; Actor JK; Zimecki M; Wise J; Płoszaj P; Mirza S; Kruzel M; Hwang SA; Ba X; Boldogh I
J Biotechnol; 2013 Dec; 168(4):666-75. PubMed ID: 24070904
[TBL] [Abstract][Full Text] [Related]
25. Improved Refolding of a Human IgG1 Fc (CH2-CH3) Scaffold from Its Inclusion Body in E. coli by Alkaline Solubilization.
Ishikawa S; Ishikawa H; Sato A
Biol Pharm Bull; 2022; 45(3):284-291. PubMed ID: 35228394
[TBL] [Abstract][Full Text] [Related]
26. [Expression of ATR-Fc fusion protein in CHO cells].
Gao LH; Hu XW; Chen W; Xu JJ; Zhao J; Chen HP
Sheng Wu Gong Cheng Xue Bao; 2005 Sep; 21(5):826-31. PubMed ID: 16285529
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human lactoferrin-Fc fusion with an improved plasma half-life.
Shiga Y; Oshima Y; Kojima Y; Sugimoto A; Tamaki N; Murata D; Takeuchi T; Sato A
Eur J Pharm Sci; 2015 Jan; 67():136-143. PubMed ID: 25433245
[TBL] [Abstract][Full Text] [Related]
28. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics.
Dumont JA; Low SC; Peters RT; Bitonti AJ
BioDrugs; 2006; 20(3):151-60. PubMed ID: 16724863
[TBL] [Abstract][Full Text] [Related]
29. Characterization of mammalian receptors for lactoferrin.
Suzuki YA; Lönnerdal B
Biochem Cell Biol; 2002; 80(1):75-80. PubMed ID: 11908646
[TBL] [Abstract][Full Text] [Related]
30. Recombinant human lactoferrin treatment for global health issues: iron deficiency and acute diarrhea.
Bethell DR; Huang J
Biometals; 2004 Jun; 17(3):337-42. PubMed ID: 15222487
[TBL] [Abstract][Full Text] [Related]
31. Mammalian cell-produced therapeutic proteins: heterogeneity derived from protein degradation.
Dorai H; Ganguly S
Curr Opin Biotechnol; 2014 Dec; 30():198-204. PubMed ID: 25118137
[TBL] [Abstract][Full Text] [Related]
32. Fc-fusion proteins: new developments and future perspectives.
Czajkowsky DM; Hu J; Shao Z; Pleass RJ
EMBO Mol Med; 2012 Oct; 4(10):1015-28. PubMed ID: 22837174
[TBL] [Abstract][Full Text] [Related]
33. Clinical Immunogenicity Risk Assessment for a Fusion Protein.
Sperinde G; Montgomery D; Mytych DT
AAPS J; 2020 Apr; 22(3):64. PubMed ID: 32246297
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
